Chelsea Therapeutics International LTD (CHTP) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
3530 TORINGDON WAY CHARLOTTE, NC 28277 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 3/31/2014 MRQ | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 45,323,062 | 28,424,631 | |||
| Cash and cash equivalents | 45,323,062 | 28,424,631 | |||
| Prepaid expense | 915,222 | ✕ | |||
| Prepaid expense and other current assets | ✕ | ✕ | 176,181 | ||
| Other undisclosed current assets | 219,660 | 175,192 | |||
| Total current assets: | 46,457,944 | 28,776,004 | |||
| Noncurrent Assets | |||||
| Property, plant and equipment | 44,578 | 151,544 | |||
| Total noncurrent assets: | 44,578 | 151,544 | |||
| TOTAL ASSETS: | 46,502,522 | 28,927,548 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,949,037 | 1,484,909 | |||
| Employee-related liabilities | 213,313 | 199,935 | |||
| Accounts payable | 1,363,485 | 788,073 | |||
| Accrued liabilities | 372,239 | 496,901 | |||
| Total current liabilities: | 1,949,037 | 1,484,909 | |||
| Noncurrent Liabilities | |||||
| Other undisclosed liabilities | 1,297,813 | 1,526,489 | |||
| Total liabilities: | 3,246,850 | 3,011,398 | |||
| Equity | |||||
| Equity, attributable to parent, including: | 43,255,672 | 25,916,150 | |||
| Common stock | 7,843 | 6,708 | |||
| Additional paid in capital | 274,725,472 | 240,970,852 | |||
| Other undisclosed equity, attributable to parent | (231,477,643) | (215,061,410) | |||
| Total equity: | 43,255,672 | 25,916,150 | |||
| TOTAL LIABILITIES AND EQUITY: | 46,502,522 | 28,927,548 | |||
Income Statement (P&L) (USD)
| 3/31/2014 TTM | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|
| Operating expenses | (16,434,356) | (31,803,503) | ||
| Operating loss: | (16,434,356) | (31,803,503) | ||
| Nonoperating income (Investment Income, Nonoperating) | 18,123 | 67,594 | ||
| Loss from continuing operations: | (16,416,233) | (31,735,909) | ||
| Loss before gain (loss) on sale of properties: | (16,416,233) | (31,735,909) | ||
| Net loss available to common stockholders, diluted: | (16,416,233) | (31,735,909) | ||
Comprehensive Income (USD)
| 3/31/2014 TTM | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|
| Net loss: | (16,416,233) | (31,735,909) | ||
| Comprehensive loss, net of tax, attributable to parent: | (16,416,233) | (31,735,909) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.